Document is current

Article History

Received: 9 March 2025

Accepted: 17 June 2025

First Online: 19 July 2025

Competing interests

: L.L.S.: Consulting or Advisory Role (Self)—AstraZeneca, Merck, Bristol Myers Squibb, Roche/Genentech, Voronoi, GlaxoSmithKline, Seattle Genetics, Arvinas, Navire, Relay Therapeutics, Daiichi Sankyo, Tubulis, Medicenna, LTZ Therapeutics, Marengo, Nerviano, Amgen, Pangea, Incyte, Gilead. Institutional Support for Clinical Trials—Bristol Myers Squibb, Roche/Genentech, GlaxoSmithKline, Merck, Novartis, Pfizer, AstraZeneca, Boehringer Ingelheim, Bayer, Amgen, Daiichi Sankyo, EMD Serono, 23Me, Astellas, Abbive, Gilead, Incyte, Legochem Biosciences, Loxo/Lilly, Medicenna, Takara Bio. Leadership Role (spouse)—Treadwell Therapeutics (Co-Founder). Stock Ownership (spouse)—Agios. D.W.C.: Consulting or Advisory Role—AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; GlaxoSmithKline; Inflex; Inivata/NeoGenomics; Lilly; Merck; Novartis; Pfizer; Roche/Genentech and Saga. Research Funding—AstraZeneca (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Inivata/NeoGenomics (Inst); Knight Therapeutics (Inst); Merck (Inst); Pfizer (Inst); ProteinQure (Inst); and Roche/Genentech (Inst). Patents, Royalties, Other Intellectual Property—Patent (US62/675,228) for methods of treating cancers characterized by a high expression level of spindle and kinetochore associated complex subunit 3 (ska3) gene. P.L.B.: Consulting or Advisory Role—Seattle Genetics; Lilly; Amgen; Merck; Gilead Sciences; Zymeworks; Repare Therapeutics; BMS; Pfizer. Research Funding—Bristol-Myers-Squibb (Inst); Sanofi (Inst); AstraZeneca (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Merck (Inst); Seattle Genetics (Inst); Amgen (Inst); Bicara (Inst); Zymeworks (Int); Medicenna (Inst); Bayer (Inst); Takeda (Inst). L.G., C.M., C.G.S., and A.C. were employees of NeoGenomics at the time of data generation and manuscript preparation. The rest of the authors report no competing interests.